← All trials
NCT06846281
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 16, 2025
- Primary completion
- Feb 10, 2030
- Completion date
- Mar 10, 2032
- First posted
- Feb 26, 2025
- Last posted
- Feb 28, 2025
- Enrollment
- 360
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovartisLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.